-$0.32 EPS Expected for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) This Quarter

Analysts expect that Accelerate Diagnostics, Inc. (NASDAQ:AXDXGet Rating) will post earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Accelerate Diagnostics’ earnings. Accelerate Diagnostics posted earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year-over-year growth rate of 22%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Accelerate Diagnostics will report full-year earnings of ($1.33) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($1.36) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Accelerate Diagnostics.

Accelerate Diagnostics (NASDAQ:AXDXGet Rating) last posted its earnings results on Tuesday, March 8th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The company had revenue of $3.30 million for the quarter, compared to the consensus estimate of $3.20 million. During the same quarter last year, the business earned ($0.33) earnings per share.

A number of research firms have recently commented on AXDX. StockNews.com began coverage on Accelerate Diagnostics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a research report on Wednesday, March 9th. Craig Hallum downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating and set a $5.00 target price on the stock. in a research report on Wednesday, March 9th. Finally, Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.42.

Shares of Accelerate Diagnostics stock traded down $0.06 during trading on Friday, reaching $0.96. The company’s stock had a trading volume of 872,241 shares, compared to its average volume of 391,538. The business’s fifty day moving average price is $1.80 and its 200-day moving average price is $3.84. The firm has a market cap of $66.87 million, a price-to-earnings ratio of -0.76 and a beta of 1.81. Accelerate Diagnostics has a one year low of $0.91 and a one year high of $9.36.

In related news, Director Hany Massarany acquired 20,000 shares of the firm’s stock in a transaction on Monday, January 31st. The shares were bought at an average cost of $3.30 per share, with a total value of $66,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 45.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Accelerate Diagnostics by 1.1% during the fourth quarter. BlackRock Inc. now owns 2,355,162 shares of the medical research company’s stock valued at $12,295,000 after purchasing an additional 24,718 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Accelerate Diagnostics by 36.1% in the 4th quarter. Baird Financial Group Inc. now owns 1,508,069 shares of the medical research company’s stock worth $7,872,000 after acquiring an additional 400,169 shares in the last quarter. Griffin Asset Management Inc. boosted its holdings in shares of Accelerate Diagnostics by 48.9% in the 1st quarter. Griffin Asset Management Inc. now owns 1,501,441 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 493,100 shares in the last quarter. State Street Corp boosted its holdings in shares of Accelerate Diagnostics by 10.6% in the 4th quarter. State Street Corp now owns 1,093,823 shares of the medical research company’s stock worth $5,710,000 after acquiring an additional 105,139 shares in the last quarter. Finally, FMR LLC boosted its holdings in shares of Accelerate Diagnostics by 16.1% in the 1st quarter. FMR LLC now owns 857,069 shares of the medical research company’s stock worth $18,016,000 after acquiring an additional 118,620 shares in the last quarter. 67.71% of the stock is currently owned by institutional investors.

About Accelerate Diagnostics (Get Rating)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.